DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis

• Published in: Diabetes research and clinical practice Vol. 116; pp. 288 - 298
• Main Authors: Mamza, Jil, Marlin, Carol, Wang, Cai, Chokkalingam, Kamal, Idris, Iskandar
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.06.2016
• Subjects: Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Endocrinology & Metabolism; Fracture; Fractures, Bone - chemically induced; Glycated Hemoglobin - metabolism; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Meta-analysis; Randomized Controlled Trials as Topic; Dipeptidyl peptidase-4 inhibitor; Fracture; Meta-analysis

•Oral glucose-lowering medications have different effects on bone metabolism.•The effect of DPP-4 inhibitor on the risk of developing bone fractures is unclear.•Meta-analysis was conducted on RCT studies to assess fracture risk of DPP-4 inhibitor.•No significant association of fracture events found...